Name: GLP 3 (Retatrutide) — 20 mg
SKU: Retatrutide 20mg
Availability: InStock

Description

Retatrutide (LY3437943) is a novel triagonist peptide that activates GLP-1, GIP, and glucagon receptors. It is studied for its powerful effects on weight management, glucose regulation, and metabolic health, representing the next generation of incretin-based therapies.

Benefits

Weight management — studied for profound reductions in body weight in phase 2 trials.
Glucose control — linked to improved HbA1c and insulin sensitivity in type 2 diabetes.
Metabolic health — explored for effects on cholesterol, liver fat, and energy balance.
Multi-pathway synergy — triagonist activity combines GLP-1, GIP, and glucagon benefits.
Next-gen incretin — represents one of the most advanced peptide approaches in obesity research.

What researchers look at

Triple receptor agonism: GLP-1, GIP, and glucagon pathways.
Clinical trials showing record-setting weight loss in obesity and diabetes populations.
Comparisons with semaglutide and tirzepatide for efficacy and tolerability.
Investigations into long-term metabolic, cardiovascular, and hepatic outcomes.

Quick Specs

Form: Lyophilized peptide
Net per vial: 20 mg
Purity: ≥99% (HPLC)
Identity: MS-verified (per COA)
Storage: 2–8 °C, protect from light

Identity Basics

Type: Triple GLP-1/GIP/glucagon receptor agonist
Formula / M.W.: Peptide analog (varies by formulation)
CAS: 2381089-83-2

Selected Research

PubChem entry — chemical identity:

https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide
Phase 2 trial in obesity (NEJM, 2023):

https://pubmed.ncbi.nlm.nih.gov/37323486/
Mechanism of action — triple agonism:

https://pubmed.ncbi.nlm.nih.gov/36006191/
Comparisons with semaglutide/tirzepatide:

https://pubmed.ncbi.nlm.nih.gov/37323485/

⚠️ Disclaimer

This product is intended for laboratory research use only.
Not for human or veterinary use.
Not approved for diagnostic, therapeutic, or medical applications.
Handle using appropriate laboratory safety procedures and personal protective equipment.